Prognostic value of survivin expression in parotid gland cancer in consideration of different histological subtypes

European Journal of Cancer

Volumn 47, Issue 7, 2011, Pages 1013-1020

  Stenner, Markus ^a   Demgensky, Ariane ^a   Molls, Christoph ^a   Hardt, Aline ^a   Luers, Jan C ^a   Grosheva, Maria ^a   Huebbers, Christian U ^b   Klussmann, Jens P ^c  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

Immunohistochemistry; Parotid gland cancer; Prognosis; Salivary gland; Survivin

Indexed keywords

SURVIVIN;

ACINAR CELL CARCINOMA; ADENOCARCINOMA; ADENOID CYSTIC CARCINOMA; ADENOSQUAMOUS CARCINOMA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CARCINOMA EX PLEOMORPHIC ADENOMA; CHILD; CYTOPLASM; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PAROTID GLAND CANCER; PLEOMORPHIC ADENOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCHOOL CHILD; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; TISSUE MICROARRAY; UNDIFFERENTIATED CARCINOMA;

APOPTOSIS; CYTOPLASM; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PAROTID NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SALIVARY GLAND NEOPLASMS;

EID: 79953703976     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.02.005     Document Type: Article

References (39)

1. Barnes L, Eveson JW, Reichart P, Sidransky D. Tumours of the salivary gland. In: Pathology and genetics. Head and neck tumours. World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2005: p. 209-81.
2. Vander Poorten VL. Salivary gland carcinoma - stepping up the prognostic ladder. 3rd ed. Amsterdam, The Netherlands: University of Amsterdam; 2002.
3. Boukheris H, Curtis RE, Land CE, Dores GM. Incidence of carcinoma of the major salivary glands according to the WHO classification, 1992 to 2006: a population-based study in the United States. Cancer Epidemiol Biomarkers Prev 2009;18:2899-906.
4. Chandana SR, Conley BA. Salivary gland cancers: current treatments, molecular characteristics and new therapies. Expert Rev Anticancer Ther 2008;8:645-52. (Pubitemid 351818358)
5. Nagliati M, Bolner A, Vanoni V, et al. Surgery and radiotherapy in the treatment of malignant parotid tumors: a retrospective multicenter study. Tumori 2009;95:442-8.
6. Hamakawa H, Nakashiro K, Sumida T, et al. Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer. Head Neck 2008;30:800-9. (Pubitemid 351913858)
7. Laurie SA, Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol 2006;24:2673-8. (Pubitemid 46622089)
8. Poorten VV, Hart A, Vauterin T, et al. Prognostic index for patients with parotid carcinoma: international external validation in a Belgian - German database. Cancer 2009;115:540-50.
9. Luukkaa H, Klemi P, Leivo I, Vahlberg T, Grenman R. Prognostic significance of Ki-67 and p53 as tumor markers in salivary gland malignancies in Finland: an evaluation of 212 cases. Acta Oncol 2006;45:669-75.
10. Jaskoll T, Chen H, Min ZY, Wu D, Melnick M. Developmental expression of survivin during embryonic submandibular salivary gland development. BMC Dev Biol 2001;1:5.
11. Schmitz M, Diestelkoetter P, Weigle B, et al. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res 2000;60:4845-9.
12. Yamamoto T, Tanigawa N. The role of survivin as a new target of diagnosis and treatment in human cancer. Med Electron Microsc 2001;34:207-12.
13. Qi H, Wang KM, Liang YQ, Yang LL. Expression and clinic pathological significance of survivin mRNA and protein in salivary gland tumors. Shanghai Kou Qiang Yi Xue 2007;16:18-23.
14. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008;8:61-70.
15. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003;22:8581-9. (Pubitemid 38019195)
16. Li F. Survivin study: what is the next wave? J Cell Physiol 2003;197:8-29.
17. Nikitakis NG, Scheper MA, Papanikolaou VS, Sauk JJ. The oncogenic effects of constitutive STAT3 signaling in salivary gland cancer cells are mediated by survivin and modulated by the NSAID sulindac. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;107:826-36.
18. Nikitakis NG, Scheper MA, Papanikolaou VS, Sklavounou A, Sauk JJ. Immunohistochemical expression of the oncogenic molecules active STAT3 and survivin in benign and malignant salivary gland tumors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;107:837-43.
19. Preuss SF, Weinell A, Molitor M, et al. Nuclear survivin expression is associated with HPV-independent carcinogenesis and is an indicator of poor prognosis in oropharyngeal cancer. Br J Cancer 2008;98:627-32. (Pubitemid 351214523)
20. Lo ML, Pannone G, Staibano S, et al. Survivin expression in oral squamous cell carcinoma. Br J Cancer 2003;89:2244-8. (Pubitemid 38168006)
21. Giefing M, Wierzbicka M, Rydzanicz M, et al. Chromosomal gains and losses indicate oncogene and tumor suppressor gene candidates in salivary gland tumors. Neoplasma 2008;55:55-60.
22. Lee S, Kim GE, Park CS, et al. Primary squamous cell carcinoma of the parotid gland. Am J Otolaryngol 2001;22:400-6. (Pubitemid 33098078)
23. Hui KK, Luna MA, Batsakis JG, Ordonez NG, Weber R. Undifferentiated carcinomas of the major salivary glands. Oral Surg Oral Med Oral Pathol 1990;69:76-83. (Pubitemid 20038493)
24. Theriault C, Fitzpatrick PJ. Malignant parotid tumors. Prognostic factors and optimum treatment. Am J Clin Oncol 1986;9:510-6. (Pubitemid 17205981)
25. Hatta C, Terada T, Okita J, et al. Clinicopathological study of undifferentiated carcinoma of the parotid gland. Auris Nasus Larynx 2003;30:273-7. (Pubitemid 36960233)
26. Khan Z, Tiwari RP, Mulherkar R, et al. Detection of survivin and p53 in human oral cancer: correlation with clinicopathologic findings. Head Neck 2009;31:1039-48.
27. Fiorella R, Di Nicola V, Fiorella ML, et al. Major salivary gland diseases. Multicentre study. Acta Otorhinolaryngol Ital 2005;25:182-90.
28. Rapidis AD, Givalos N, Gakiopoulou H, et al. Mucoepidermoid carcinoma of the salivary glands. Review of the literature and clinicopathological analysis of 18 patients. Oral Oncol 2007;43:130-6.
29. Preuss SF, Weinell A, Molitor M, et al. Survivin and epidermal growth factor receptor expression in surgically treated oropharyngeal squamous cell carcinoma. Head Neck 2008;30:1318-24.
30. Altieri DC. New wirings in the survivin networks. Oncogene 2008;27:6276-84.
31. Munger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res 2002;89:213-28. (Pubitemid 35351540)
32. Hauser U, Balz V, Carey TE, et al. Reliable detection of p53 aberrations in squamous cell carcinomas of the head and neck requires transcript analysis of the entire coding region. Head Neck 2002;24:868-73. (Pubitemid 34913258)
33. Lee J, Kang WK, Park JO, et al. Expression of activated signal transducer and activator of transcription 3 predicts poor clinical outcome in gastric adenocarcinoma. APMIS 2009;117:598-606.
34. Ito S, Oyake T, Murai K, Ishida Y. Deguelin suppresses cell proliferation via the inhibition of survivin expression and STAT3 phosphorylation in HTLV-1-transformed T cells. Leuk Res 2010;34:352-7.
35. Zhang X, Yue P, Fletcher S, et al. A novel small-molecule disrupts STAT3 SH2 domain-phosphotyrosine interactions and STAT3-dependent tumor processes. Biochem Pharmacol 2010.
36. Chesnokov V, Sun C, Itakura K. Glucosamine suppresses proliferation of human prostate carcinoma DU145 cells through inhibition of STAT3 signaling. Cancer Cell Int 2009;9:25.
37. Altieri DC. Targeted therapy by disabling crossroad signaling networks: the survivin paradigm. Mol Cancer Ther 2006;5:478-82.
38. Harada K, Kawaguchi S, Supriatno, et al. Enhancement of apoptosis in salivary gland cancer cells by the combination of oral fluoropyrimidine anticancer agent (S-1) and radiation. Int J Oncol 2004;25:905-11.
39. Eto M, Kodama S, Uemura N, Suzuki M. Antibody responses to survivin and their clinical significance in patients with head and neck cancer. Head Neck 2007;29:1128-35.